Neoplasms

Urinary Tract, Sexual Organs, and Pregnancy Conditions

All Conditions

Infections

Symptoms and General Pathology

Prostatic Neoplasms

Mycobacterium Infections

Communicable Diseases

Genital Neoplasms, Male

Urogenital Neoplasms

Genital Diseases

Genital Diseases, Male

Urogenital Diseases

Prostatic Diseases

Male Urogenital Diseases

Bacterial Infections

Gram-Positive Bacterial Infections

Mycoses

Bacterial Infections and Mycoses

All Drugs and Chemicals

Antineoplastic Agents

Hormones

Docetaxel

Immunomodulating Agents

Adjuvants, Immunologic

Tubulin Modulators

Antimitotic Agents

Mycobacterium w.

Sudhir Rawal, MD

Arup Kumar Mandal, MD

Devakar Dalela, MD

N K Mohanty, M.D.

Jayesh Dhabalia, MD

Arun Chawla, MD

Sujata Patwardhan, MD

P G Jayaprakash, MD

Amil Lal Bhat, MD

Raju T Chacko, MD

Sushil Bhatia, MD

Kim Mammen, MD

K C Lakshmaiah, MD

Rajeev Gupta, MD

This study proposed the comparison the overall survival, hematological toxicity, pain reduction score,PSA levels, tumor response, quality of life in two arms of HRPC patients from different parts of India.

Prostate Cancer is a common health issue facing men worldwide in most of the patients cancer will shrink with hormonal therapy. In some cases cancer returns or continues to grow despite very low levels of circulating male hormones, which is called Androgen-Independent Prostate Cancer (AIPC) or Hormone Refractory Prostate Cancer (HRPC). Mycobacterium w is known to share multiple antigen including PSA. It administration is associated with antigen specific generation of cell mediated immunity. Docetaxel is found to useful in management of metastatic hormone refractory prostate cancer, which is associated with improved survival, tumor progression free survival with reduction in pain, serum PSA and improvement in quality of life. Cyclophosphamide 300mg/sq.m will be used to eliminate T-regulatory cell responsible immuno suppression. The vaccine Mycobacterium w will be administered on a day following cyclophosphamide. For better initiation of immune responses Docetaxel will be given seven days following first dose of Mycobacterium w.

A Study of Mycobacterium w Plus Docetaxel for Hormone Refractory Metastatic Prostate Cancer

Open Label, Randomized Multicentric Phase II Clinical Trial of Mycobacterium w in Combination With Docetaxel Versus Docetaxel in Metastatic Hormone Refractory Prostate Cancer.

Cadila Pharnmaceuticals

Respiratory Tract (Lung and Bronchial) Diseases

Lung Neoplasms

Carcinoma, Non-Small-Cell Lung

Carcinoma

Respiratory Tract Neoplasms

Thoracic Neoplasms

Lung Diseases

Respiratory Tract Diseases

Carcinoma, Bronchogenic

Bronchial Neoplasms

Paclitaxel

Albumin-Bound Paclitaxel

Cisplatin

Paclitaxel & Cisplatin

R K Chaudhary, MD

Anup Majumdar, MD

A. Rajkumar, MD

Rajeev Seam, MD

A.K. Patel, MD

Chanchal Goswami, MD

Jaydip Biswas, MD

Ritwik Pandyea, MD

Aloke G Dastidar, MD

Narayanankutty Warrier, MD

Ashutosh N Aggarwal, MD

Apurva Patel, MD

Santanu Chaudhary, MD

Rajeev Prasad, MD

Ramakrishna Malladi, MD

The purpose of this study is to determine whether Mycobacterium w in combination with Paclitaxel plus Cisplatin are effective in Advanced Non Small Cell Lung cancer.

Non-small cell lung cancer (NSCLC) accounts for 75% of all lung cancers. majority of patients of NSCLC patients are stage IIIA or IIIB patients are suitable for radiotherapy, which could not improve the survival rates of 5-10%. This study proposed Mycobacterium w (heat killed) in combination chemotherapy of Cisplatin and Paclitaxel along with radiotherapy for adjuvant therapy management of NSCLC in controlled clinical trial, which may prove the efficacy, better survival rate and quality of life.

A Study of Mycobacterium w in Combination With Paclitaxel Plus Cisplatin in Advanced Non Small Cell Lung Cancer

Open Label, Randomized Multicentric Phase II Clinical Trial of Mycobacterium w in Combination With Paclitaxel Plus Cisplatin Versus Paclitaxel and Cisplatin in Advanced Non Small Cell Lung Cancer.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
A Study of Mycobacterium w Plus Docetaxel for Hormone Refractory Metastatic Prostate Cancer	NCT00525408	Hormone Refract...	Mycobacterium w... Docetaxel	18 Years -	Cadila Pharnmaceuticals
A Study of Mycobacterium w in Combination With Paclitaxel Plus Cisplatin in Advanced Non Small Cell Lung Cancer	NCT00680940	Non Small Cell ...	Paclitaxel & Ci... Mycobacterium w...	18 Years -	Cadila Pharnmaceuticals
A Study of Mycobacterium w Plus Docetaxel for Hormone Refractory Metastatic Prostate Cancer	NCT00525408	Hormone Refract...	Mycobacterium w... Docetaxel	18 Years -	Cadila Pharnmaceuticals
A Study of Mycobacterium w in Combination With Paclitaxel Plus Cisplatin in Advanced Non Small Cell Lung Cancer	NCT00680940	Non Small Cell ...	Paclitaxel & Ci... Mycobacterium w...	18 Years -	Cadila Pharnmaceuticals

Spots Global Cancer Trial Database for mycobacterium w.